Disappointing results from STEADFAST, a phase 3 study of Azeliragon (TTP488) in #Alzheimer's disease. Not surprising given its history. $VTVT https://t.co/wJje1fPpcc https://t.co/BDJQfvH1wl https://t.co/nyOXNmNvfT https://t.co/fNW2ib5Vg8
751 followers
3 followers
@JuliaSkripkaSer Here is the changes from baseline in ADAS-cog for each quintile TTP488 concentration range over 18 months of treatment. I'm assuming that the 1st/2nd lowest conc. range is reflective of the residual concentration & effect post-dose dis
3 followers
@JuliaSkripkaSer Half life info link: https://t.co/91IPoEBZiv
9,979 followers
9 Re-analysis of same data as above Effect of TTP488 in patients with mild to moderate Alzheimer's disease https://t.co/Xi9FlQW9mb